- Meditech Anteris Technologies (AVR) has raised $1.1 million via a placement to help fuel its work developing a 3D heart valve
- Anteris raised the new cash via the issue of 316,954 new shares at $3.37, a 10 percent discount to the last closing price
- The new cash will provide working capital for the medical technology company as it progresses the development of DurAVR
- In March 2020, Anteris began the first-in-human study, evaluating the efficacy of the technology in 15 patients
- The study not expected to conclude until March 2021 but early data shows DurAVR is easy to implant, creates a wider valve, and restores normal blood flow dynamics
- AVR shares suspended from quotation and last traded on December 22 at $3.75
